MPLT — MapLight Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1770069 ·
Last close
$8.83
Market Cap
$385.43M
52W High
$40.43
52W Low
$8.71
ADV30
506,105
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -63,548,000 | -60,192,000 | 368,348,000 | 71,633,000 | 20,049,000 |
| Mar 2026 | 0 | — | -64,503,000 | -60,668,000 | 418,788,000 | 55,707,000 | 18,954,000 |
| Dec 2025 | 0 | — | -83,377,000 | -79,548,000 | 479,512,000 | 46,729,000 | 21,140,000 |
| Sep 2025 | 0 | — | -31,498,000 | -29,418,000 | 257,222,000 | 64,146,000 | 23,706,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-151,286,000
Investing CF
$-278,740,000
Financing CF
$463,177,000
CapEx
$-537,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.06
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-421,188,000
Inventory
—
Receivables
—
ST Investments
$254,406,000
EBIT TTM
$-202,921,000
Pretax Income TTM
$-191,974,000
Interest Exp TTM
—
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -169,083,000 | -161,152,000 | 479,512,000 | 21,140,000 | 458,372,000 | -138,137,000 |
| Dec 2024 | — | — | — | — | 21,721,000 | 115,195,000 | — |
| Dec 2023 | — | — | — | — | 20,127,000 | 71,282,000 | — |
| Dec 2022 | — | — | — | — | 18,519,000 | 20,870,000 | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$418,788,000
Forward EPS
$-3.30
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $8.83 · call volume: 9 · put volume: 80
Expected Move to 2026-10-16:
±$2.10
(23.84%) —
implied range
$6.72 –
$10.93
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IRD | Opus Genetics, Inc. | $386.86M | $4.65 | — |
| ARCT | Arcturus Therapeutics Holdings Inc. | $390.53M | $13.74 | — |
| GALT | GALECTIN THERAPEUTICS INC | $397.35M | $3.94 | — |
| PTCHF | PureTech Health plc | $370.22M | $1.51 | — |
| TTRX | Turn Therapeutics Inc. | $364.41M | $12.00 | — |
News headlines (Yahoo Finance, 1h cache)
MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics
2026-10-06 11:00 · Yahoo
MapLight Therapeutics to Participate in Upcoming Investor Conference
2026-09-09 11:00 · Yahoo
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-13 20:05 · Yahoo
MapLight Therapeutics Launching $150 Million Private Placement Financing
2026-08-13 13:47 · Yahoo
MapLight Therapeutics Announces $150 Million Private Placement Financing
2026-08-13 13:10 · Yahoo
MapLight Therapeutics stock crashes on Phase II schizophrenia data
2026-07-28 15:06 · Yahoo
MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose
2026-07-27 23:08 · Yahoo
Maplight Therapeutics’ Schizophrenia Drug Hits Phase II Primary Endpoint
2026-07-27 17:02 · Yahoo
Is MapLight Therapeutics (MPLT) Fully Valued As Its Shares Hold Near $36.56?
2026-07-26 14:07 · Yahoo
Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout?
2026-06-30 13:22 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.